Evidence map›Paper›PMID 38528182›Full record

ArticleThe EMBO journal2024

Regulation of Zbp1 by miR-99b-5p in microglia controls the development of schizophrenia-like symptoms in mice.

Lalit Kaurani, Md Rezaul Islam, Urs Heilbronner, Dennis M Krüger, Jiayin Zhou, Aditi Methi, Judith Strauss, Ranjit Pradhan, Sophie Schröder, Susanne Burkhardt and 19 more

Open access · diamondAbstract read
In one paragraph

Article in The EMBO journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. lncRNAbioRxiv : the preprint server for biology · 2025
    Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 11 institutions in 3 countries.

Lalit Kaurani *Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany. lalit.kaurani@dzne.de.ORCID http://orcid.org/0000-0002-2304-6111
Md Rezaul Islam *Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany.
Urs Heilbronner *Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.
Dennis M KrügerDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany.
Jiayin ZhouDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany.
Aditi MethiDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany.ORCID http://orcid.org/0009-0000-7585-4615
Judith StraussInstitute for Neuroimmunology and Multiple Sclerosis Research, University Medical Center Göttingen, Göttingen, Germany.
Ranjit PradhanDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany.
Sophie SchröderDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany.
Susanne BurkhardtDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany.
Anna-Lena SchuetzDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany.
Tonatiuh PenaDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany.ORCID http://orcid.org/0000-0002-9329-8912
Lena ErlebachDepartment of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Germany; Germany and German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Anika BühlerDepartment of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Germany; Germany and German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Monika BuddeInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.
Fanny SennerInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.
Mojtaba Oraki KohshourInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.
Eva C SchulteInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.
Max SchmaußClinic for Psychiatry, Psychotherapy and Psychosomatics, Augsburg University, Medical Faculty, Bezirkskrankenhaus Augsburg, Augsburg, 86156, Germany.
Eva Z ReininghausDepartment of Psychiatry and Psychotherapeutic Medicine, Research Unit for Bipolar Affective Disorder, Medical University of Graz, Graz, 8036, Austria.
Georg JuckelDepartment of Psychiatry, Ruhr University Bochum, LWL University Hospital, Bochum, 44791, Germany.
Deborah Kronenberg-VersteegDepartment of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Germany; Germany and German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Ivana DelalleDepartment of Pathology, Lifespan Academic Medical Center, Alpert Medical School of Brown University, Providence, RI, 02903, USA.
Francesca OdoardiInstitute for Neuroimmunology and Multiple Sclerosis Research, University Medical Center Göttingen, Göttingen, Germany.
Alexander FlügelInstitute for Neuroimmunology and Multiple Sclerosis Research, University Medical Center Göttingen, Göttingen, Germany.
Thomas G SchulzeInstitute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany. thomas.schulze@med.uni-muenchen.de.ORCID http://orcid.org/0000-0001-6624-2975
Peter FalkaiDepartment of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany. peter.falkai@med.uni-muenchen.de.ORCID http://orcid.org/0000-0003-2873-8667
Farahnaz SananbenesiResearch Group for Genome Dynamics in Brain Diseases, 37077, Göttingen, Germany. fsananb@gwdg.de.ORCID http://orcid.org/0000-0002-2123-7694
Andre FischerDepartment for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany. a.fischer@mail.gwdg.de.ORCID http://orcid.org/0000-0001-8546-1161
German Center for Neurodegenerative Diseases · DELudwig-Maximilians-Universität München · DEHertie Institute for Clinical Brain Research · DEUniversitätsmedizin Göttingen · DELMU Klinikum · DEBezirkskrankenhaus Augsburg · DEBrown University · USLWL-Universitätsklinikum Bochum · DEMedical University of Graz · ATSystems Dynamics (United States) · USUniversity of Bonn · DE

Funding

Bundesministerium für Bildung und Forschung (BMBF) 01EE1404HBundesministerium für Bildung und Forschung (BMBF) ERA-NET Neuron EPINEURODEVOBundesministerium für Bildung und Forschung (BMBF) GoBIOChan Zuckerberg Initiative (CZI) (2020-221779(5022) & 2021-235147)Deutsche Forschungsgemeinschaft (DFG) 514201724Deutsche Forschungsgemeinschaft (DFG) FA 241/16-1Deutsche Forschungsgemeinschaft (DFG) GRK2824Deutsche Forschungsgemeinschaft (DFG) SCHU 1603/4-1,5-1,7-1Deutsche Forschungsgemeinschaft (DFG) SPP1738,SFB1286,EXC 2067/1,EPIFUSDr. Lisa Oehler Foundation FellowshipEC | Horizon 2020 Framework Programme (H2020) PSY-PGx,grant agreement No 945151EU Joint Programme - Neurodegenerative Disease Research (JPND) EPI-3EIMPRS-GS FellowshipIMPRS-MMFD FellowshipIMPRS-Neuroscience FellowshipStudienstiftung des Deutschen Volkes (Studienstiftung) Fellowship
6 · The paper itself

Abstract

Current approaches to the treatment of schizophrenia have mainly focused on the protein-coding part of the genome; in this context, the roles of microRNAs have received less attention. In the present study, we analyze the microRNAome in the blood and postmortem brains of schizophrenia patients, showing that the expression of miR-99b-5p is downregulated in both the prefrontal cortex and blood of patients. Lowering the amount of miR-99b-5p in mice leads to both schizophrenia-like phenotypes and inflammatory processes that are linked to synaptic pruning in microglia. The microglial miR-99b-5p-supressed inflammatory response requires Z-DNA binding protein 1 (Zbp1), which we identify as a novel miR-99b-5p target. Antisense oligonucleotides against Zbp1 ameliorate the pathological effects of miR-99b-5p inhibition. Our findings indicate that a novel miR-99b-5p-Zbp1 pathway in microglia might contribute to the pathogenesis of schizophrenia.

Indexed as

MicroRNAsSchizophreniaAnimalsHumansMiceMicrogliaRNA-Binding ProteinsMicroRNAsMirn99 microRNA, mouseRNA-Binding ProteinsZbp1 protein, mouseMicrogliamicroRNAmiR-99bSchizophreniaZbp1

Identifiers

PMID38528182
PMCPMC11021462
OpenAlexW4393144233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.